Komori
Daito Pharmaceutical (4577) · TargetUpdated investment amount for 大和薬品工業

Daiwa Pharmaceutical Industry to Increase Active Pharmaceutical Ingredient Production Capacity

First written in FY2016. 1 of 6 entries say "Softened", first in FY2017. Latest entry: FY2025.

6entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2018AdvancedFY2020OtherFY2024 – FY20252016: 120162017: 120172018: 120182019: 020192020: 120202021: 020212022: 020222023: 020232024: 120242025: 12025
Same theme, other companies
Expansion and renewal of 大和薬品工業's API manufacturing facilitiesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025Updated investment amount for 大和薬品工業Annual report

    「In addition, the subsidiary 大和薬品工業㈱ invested ¥309 million in the rationalization, maintenance and renewal of its API plant.」

    The investment amount for the rationalization, maintenance and renewal of 大和薬品工業's API plant was updated from the previously reported ¥238 million to ¥309 million.
  2. FY2024Updated investment amount for 大和薬品工業Annual report

    「In addition, the subsidiary 大和薬品工業㈱ invested ¥238 million in the rationalization, maintenance and renewal of its API plant.」

    For 大和薬品工業, the investment amount for the rationalization, maintenance and renewal of its API plant was updated from the previously reported ¥187 million to ¥238 million.
  3. FY2020AdvancedAnnual report

    「In addition, the subsidiary 大和薬品工業㈱ invested ¥187 million in the rationalization, maintenance and renewal of its API plant.」

    大和薬品工業 invested ¥187 million in the rationalization, maintenance and renewal of its API plant, up from the ¥148 million reported for the previous fiscal year.
  4. FY2018RestatedAnnual report

    「In addition, the subsidiary 大和薬品工業㈱ invested ¥148 million in the rationalization, maintenance and renewal of its API plant.」

    For 大和薬品工業, the target of a 15% increase in production capacity was not reiterated, and the investment was reported as spending on the rationalization, maintenance and renewal of its API plant.
  5. FY2017SoftenedAnnual report

    「The subsidiary 大和薬品工業㈱ invested ¥694 million in the rationalization, maintenance and renewal of its API plant.」

    The specific plan to increase production capacity by 15% from the previous fiscal year was not reiterated for the current fiscal year, and the investment was reported as spending on rationalization, maintenance and renewal.
  6. FY2016First statedAnnual report

    「The Company plans to increase production capacity by 15% compared with the existing API manufacturing facilities of 大和薬品工業㈱.」

    API manufacturing facilities plan, begun in May 2016 and scheduled for completion in December 2016.
Moved together

"Expected Expansion of the Generic Drug Market" moved the same way as this thread, in the same document, in 2 of its 6 moves.

22★12
  1. ★This thread
  2. 1Expected Expansion of the Generic Drug Market2×
  3. 2Restructuring the Group's production system and strengthening coordination2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Daito Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Daiwa Pharmaceutical Industry to Increase Active Pharmaceutical Ingredient Production Capacity | Daito Pharmaceutical Co.,Ltd. (4577) | Komori